title: Correlation between changes in quality of life and symptomatic improvement in Chinese patients switched from typical antipsychotics to olanzapine.
abstract: OBJECTIVE
  The aim of this study was to investigate the correlation between changes in symptoms and changes in self-reported quality of life among Chinese patients with schizophrenia who were switched from a typical antipsychotic to olanzapine during usual outpatient care.
  
  
  METHODS
  This post hoc analysis was conducted using data from the Chinese subgroup (n=475) of a multicountry, 12-month, prospective, noninterventional, observational study. The primary publication previously reported the efficacy, safety, and quality of life among patients who switched from a typical antipsychotic to olanzapine. Patients with schizophrenia were included if their symptoms were inadequately controlled with a typical antipsychotic and they were switched to olanzapine. Symptom severity was measured using the Brief Psychiatric Rating Scale (BPRS) and the Clinical Global Impressions-Severity scale (CGI-S). Health-Related Quality of Life (HRQOL) was assessed using the World Health Organization Quality of Life-Abbreviated (WHOQOL-BREF). Paired t-tests were performed to assess changes from baseline to endpoint. Pearson's correlation coefficients (r) were used to assess the correlations between change in symptoms (BPRS and CGI-S scores) and change in HRQOL (WHOQOL-BREF scores).
  
  
  RESULTS
  Symptoms and HRQOL both improved significantly over the 12 months of treatment (P<0.001). Significant correlations were observed between changes from baseline to end of study on the BPRS and the CGI-S and each of the WHOQOL-BREF four domain scores and two overall quality-of-life questions. The correlation coefficients ranged from r=-0.45 to r=-0.53 for the BPRS and WHOQOL-BREF. The correlation coefficients were slightly smaller between the CGI-S and WHOQOL-BREF, ranging from r=-0.33 to r=-0.40.
  
  
  CONCLUSIONS
  For patients with schizophrenia, assessing quality of life has the potential to add valuable information to the clinical assessment that takes into account the patient's own perspective of well-being.
authors: Global Patient Outcomes and Real World Evidence, Eli Lilly Australia Pty Ltd, West Ryde, NSW, Australia.
authors: William
authors: W
authors: Montgomery
authors: Real World Analytics Capabilities, Eli Lilly GmbH, Vienna, Austria.
authors: Zbigniew
authors: Z
authors: Kadziola
authors: Real World Analytics, Eli Lilly and Company, Indianapolis, IN, USA.
authors: Wenye
authors: W
authors: Ye
authors: Lilly Suzhou Pharmaceutical Company, Ltd, Shanghai, People's Republic of China.
authors: Hai Bo
authors: HB
authors: Xue
authors: Lilly Suzhou Pharmaceutical Company, Ltd, Shanghai, People's Republic of China.
authors: Li
authors: L
authors: Liu
authors: Neuroscience Research, Eli Lilly and Company, Budapest, Hungary.
authors: Tamás
authors: T
authors: Treuer
keywords: data correlation; olanzapine; quality of life; schizophrenia; signs and symptoms
references: Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jan 30;31(1):32-40
references: 16843580
references: Schizophr Res. 2006 Jan 1;81(1):1-15
references: 16202565
references: Pharmacopsychiatry. 2005 Jan;38(1):6-12
references: 15706459
references: Schizophr Res. 2009 Feb;107(2-3):275-85
references: 19013769
references: Schizophr Bull. 1987;13(2):261-76
references: 3616518
references: PLoS One. 2012;7(5):e37087
references: 22615901
references: Soc Psychiatry Psychiatr Epidemiol. 2002 Nov;37(11):510-8
references: 12395140
references: Schizophr Res. 2007 Mar;91(1-3):178-86
references: 17303388
references: Schizophr Bull. 1984;10(3):388-98
references: 6474101
references: CNS Drugs. 2004;18(13):877-93
references: 15521791
references: Eur Psychiatry. 2012 Aug;27(6):432-6
references: 21602034
references: Psychiatry Res. 2013 Oct 30;209(3):291-6
references: 23473656
references: J Clin Psychiatry. 2007 Mar;68(3):368-79
references: 17388705
references: Eur Psychiatry. 2005 Oct;20 Suppl 3:S313-7
references: 16459242
references: Psychopharmacology (Berl). 2002 Jun;162(1):3-10
references: 12107610
references: BMC Psychiatry. 2011 Dec 28;11:203
references: 22204569
references: J Clin Psychiatry. 2006 Sep;67(9):1397-403
references: 17017826
references: Schizophr Bull. 2007 Sep;33(5):1225-37
references: 17204532
references: Schizophr Bull. 2012 Mar;38(2):304-15
references: 20624752
references: Pharmacoeconomics. 2012 Mar;30(3):183-95
references: 22263841
references: Int J Clin Pract. 2009 Nov;63(11):1578-88
references: 19780867
references: Expert Rev Pharmacoecon Outcomes Res. 2013 Jun;13(3):343-9
references: 23763531
references: Br J Psychiatry. 1979 Apr;134:382-9
references: 444788
references: Neurosci Lett. 2011 Oct 3;503(2):141-6
references: 21888948
references: Schizophr Res. 2001 May 30;50(1-2):79-88
references: 11378316
references: Am J Psychiatry. 2007 Jul;164(7):1061-71
references: 17606658
references: Am J Psychiatry. 2004 Feb;161(2 Suppl):1-56
references: 15000267
references: Soc Psychiatry Psychiatr Epidemiol. 2004 May;39(5):337-49
references: 15133589
references: Schizophr Res. 2002 Oct 1;57(2-3):201-8
references: 12223251
references: Psychopharmacol Bull. 1988;24(1):122-4
references: 3387516